This HTML5 document contains 136 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n10http://dx.doi.org/10.1182/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q36058584
rdf:type
wikibase:Item
schema:description
مقالهٔ علمی 2012年論文 artículu científicu espublizáu en 2012 vitskapeleg artikkel სამეცნიერო სტატია artigo científico научни чланак artikull shkencor 2012年论文 ২০১২-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ bài báo khoa học naučni članak מאמר מדעי επιστημονικό άρθρο 2012년 논문 2012年论文 wissenschaftlicher Artikel vědecký článek บทความทางวิทยาศาสตร์ article scientifique (publié 2012) article científic videnskabelig artikel (udgivet 2012) 2012年論文 scienca artikolo наукова стаття, опублікована в травні 2012 научна статия articol științific vetenskaplig artikel artykuł naukowy 2012年論文 мақолаи илмӣ vitenskapelig artikkel научни чланак vedecký článok tudományos cikk 2012年论文 article scientific artigo científico (publicado na 2012) 2012 nî lūn-bûn artikulong pang-agham scientific article 2012年论文 գիտական հոդված مقالة علمية 2012年論文 научная статья tieteellinen artikkeli 2012年論文 bilimsel makale سائنسی مضمون 2012年论文 artículo científico publicado en 2012 wetenschappelijk artikel artigo científico (publicado na 2012) teaduslik artikkel мақолаи илмӣ 2012年论文 mokslinis straipsnis articolo scientifico 2012年の論文
p:P577
wds:Q36058584-81CA30BF-49DA-452A-8B45-FF6C89A98825
wdt:P577
2012-05-18T00:00:00Z
p:P407
wds:Q36058584-2ECF6DF6-C02C-400D-8CC2-E11504FB420B
wdt:P407
wd:Q1860
p:P2860
wds:Q36058584-9E7BD431-C05F-4598-8D26-5C5B53A4DE08 wds:Q36058584-A8ADEFF3-3FA3-48BC-9814-F18DE54FC3F0 wds:Q36058584-CA307B6C-33BA-4BBC-B709-D9A50E699726 wds:Q36058584-D824C081-B608-42D4-94BD-E76F3DA388E0 wds:Q36058584-D8721C06-2489-4D7D-A63C-C8BCF0481EC5 wds:Q36058584-6F12C08C-333F-42D3-B49F-8B3CDE7685A2 wds:Q36058584-7E09918B-C475-4E3F-94F3-8D0AE4B4A75C wds:Q36058584-4869AEA2-52EB-4F29-801D-119FD0BEA746 wds:Q36058584-4F5D71F0-1E1A-4233-82B1-AF89AA5BD4E5 wds:Q36058584-642A2C17-A924-4BFE-A208-7C3DBC923BC9 wds:Q36058584-6A477CF0-3FB5-453E-81D8-51234545C336 wds:Q36058584-1B293A81-3A68-42A6-97EF-3253FE9DBCA7
wdt:P2860
wd:Q36624952 wd:Q85084463 wd:Q33493683 wd:Q47582438 wd:Q24324634 wd:Q37082736 wd:Q33594562 wd:Q40558080 wd:Q28203306 wd:Q34549230 wd:Q47596145 wd:Q53510360
p:P2093
wds:Q36058584-4B6CE691-ABFF-4C36-8C5D-CA73A51D34E4 wds:Q36058584-2A845423-66EA-4DF9-8FA4-1087E361B9A7 wds:Q36058584-2643EE78-91A2-4B89-B519-22D99B979CF9 wds:Q36058584-273A8988-6D25-4087-8FF1-499FAC87BDAC wds:Q36058584-1D238B90-30B1-43F9-93A0-0109C482F3A9 wds:Q36058584-019610F9-0B2D-4EF1-B743-8D19D33F4C7C wds:Q36058584-14952081-9F0A-415E-95BB-C37DB4822419 wds:Q36058584-B8B5EA74-78C5-41BA-9722-0FF31ECD2E44
wdt:P2093
Sandra H Thomas Ajay K Gopal Robert Chen Joycelynne M Palmer Len Farol Auayporn Nademanee Stephen J Forman Ni-Chun Tsai
rdfs:label
Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma
skos:prefLabel
Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma
schema:name
Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma
p:P1476
wds:Q36058584-7864C218-6FBD-4B23-A394-0E6D9BBE0313
wdt:P1476
Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma
p:P304
wds:Q36058584-30ECAC6F-FFEE-4EC1-8AA8-BA291C7AB584
wdt:P304
6379-6381
p:P31
wds:Q36058584-9985A6A9-E8F4-4DE6-84C9-8C7D1212E600
wdt:P31
wd:Q13442814
p:P921
wds:Q36058584-533AE678-62F9-4F0C-96D4-DB668B71703A
wdt:P921
wd:Q209369
p:P698
wds:Q36058584-9E196F64-8012-4B0B-AC8E-A46C73D37457
wdtn:P698
n11:22611160
wdt:P698
22611160
p:P1433
wds:Q36058584-8328A546-4F86-473C-AD7B-45B03BC7A1FF
wdt:P1433
wd:Q885070
p:P433
wds:Q36058584-9396DC32-7712-4FA4-A478-41BF864EECED
p:P478
wds:Q36058584-C70BFDDC-6A64-4B50-BC7C-5247D2A3585E
wdt:P433
26
wdt:P478
119
p:P356
wds:Q36058584-A485C8C5-EF37-4EB7-BB3B-88E5BC274068
wdtn:P356
n10:BLOOD-2012-03-418673
wdt:P356
10.1182/BLOOD-2012-03-418673
p:P932
wds:Q36058584-5738A9C3-5C74-4166-8615-F7C4DCED9F79
wdt:P932
3383201